Nippon India Pharma Fund
Nippon India Mutual Fund · Sectoral / Thematic · Regular Growth · AMFI 102431 · ISIN INF204K01968
NAV₹591.242920 Nov 2026
3Y return+16.91%a year
5Y return+14.37%a year
Expense ratio1.83%₹9,087 Cr
Growth Score78.1★★★★★
Returns
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 7Y | 10Y | Since launch |
| Fund | +11.32% | +3.52% | +8.09% | +16.05% | +14.27% | +16.91% | +14.37% | +21.46% | +15.58% | +17.64% |
| NIFTY Pharma TRI | +10.85% | +7.49% | +14.67% | +25.66% | +25.86% | +22.31% | +16.87% | — | — | — |
| Category middle | +6.83% | +0.56% | +8.02% | +3.99% | +3.08% | +13.34% | +11.84% | +16.65% | +14.59% | — |
Risk (36 months)
| Volatility | 14.10% |
| Sharpe | 0.74 |
| Sortino | 1.15 |
| Beta | 0.89 |
| Alpha | -2.75% |
| Deepest fall | -47.36% |
| 1-year periods with a loss | 23% |
| 5Y SIP XIRR | +17.18% |
Top holdings (31 Oct 2026)
| Sun Pharmaceutical Industries Limited | 11.55% |
| Divi's Laboratories Limited | 6.73% |
| Cipla Limited | 6.21% |
| Lupin Limited | 6.16% |
| Dr. Reddy's Laboratories Limited | 6.13% |
| Apollo Hospitals Enterprise Limited | 5.10% |
| Mankind Pharma Limited | 4.40% |
| Sai Life Sciences Limited | 4.04% |
| Ajanta Pharma Limited | 3.53% |
| Max Healthcare Institute Limited | 3.31% |
| IPCA Laboratories Limited | 2.90% |
| GlaxoSmithKline Pharmaceuticals Limited | 2.83% |
Sectors
| Pharmaceuticals & Biotechnology | 75.0% |
| Healthcare Services | 21.8% |
| Retailing | 2.3% |
| Healthcare Equipment & Supplies | 0.5% |
Calculated by Growth Analyser from AMFI NAVs and the fund house's disclosed portfolio. Up to 1 year: total return; longer: CAGR. Research and education only; not investment advice. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not indicate future returns.